The massive GAAP EPS miss (-$0.68 vs -$0.22 consensus) driven by $168M other operating expense and a $93M tax provision will likely pressure the stock near-term despite the revenue beat and strong guidance. Watch the earnings call for clarity on the other operating expense line and whether the FY2027 adjusted EBITDA margin guidance of ~16% implies meaningful GAAP improvement. The MiniMed Flex launch this month and Abbott partnership extension are positive catalysts but may take time to flow through to GAAP profitability.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $14.26entry
- T+1 · 6mo ago −1.40%α −1.80% · $14.06
- T+5 · 5mo ago +3.16%α +6.98% · $14.71
- T+20 · 5mo ago +9.33%α +10.33% · $15.59
- T+60 · 3mo ago +36.82%α +34.32% · $19.51
Price Chart
How similar events traded
Executive Summary
MiniMed reported Q4 FY2026 net sales of $837M (+15.6% YoY as reported, +8.7% organic), surpassing $3B in annual revenue for the first time. The company guided FY2027 organic revenue growth of ~10% and adjusted EBITDA margin of ~16%. However, GAAP net loss widened to -$183M in Q4 (from -$168M a year ago) and EPS was -$0.68, significantly below the -$0.22 consensus estimate, driven by $168M in other operating expense and a $93M income tax provision. The combination of strong top-line growth and expanding product pipeline with deteriorating GAAP profitability and a massive EPS miss creates a mixed picture.
Key Financial Metrics
Key Facts
- Q4 FY2026 net sales $837M, +15.6% as reported YoY, +8.7% organic
- Full-year FY2026 net sales $3.102B, +14.2% as reported, +8.0% organic (first time above $3B)
- GAAP net loss attributable to company Q4: -$183M vs -$172M YoY; FY: -$331M vs -$213M YoY
- GAAP diluted EPS Q4: -$0.68 (vs consensus -$0.22); FY: -$1.29 vs -$0.84
- FY2027 guidance: organic revenue growth ~10% (incl. 1.0-1.5% extra-week benefit), adjusted EBITDA margin ~16%
- CGM revenue grew 21.6% in Q4 to $420M; pumps declined 5.5% to $146M due to MiniMed Flex launch timing
- International net sales grew 22.4% as reported in Q4; U.S. grew only 1.5% as customers waited for Flex launch
- Abbott partnership extended to develop dual glucose-ketone sensors for MiniMed systems
Financial Impact
Q4 GAAP EPS -$0.68 vs consensus -$0.22 (miss of -209%); Q4 revenue $837M vs consensus $826.5M (beat of +1.3%)
Risk Factors
- GAAP profitability continues to deteriorate with operating loss widening to -$91M in Q4 from -$148M a year ago
- U.S. revenue growth stalled at 1.5% as customers delayed purchases for MiniMed Flex, execution risk on new product ramp
- Other operating expense surged to $168M in Q4 from $4M a year ago, unclear if this is recurring
- Income tax provision of $93M on a pre-tax loss of -$90M is unusual and may raise questions about deferred tax valuation allowances
- Pump sales declined 5.5% YoY in Q4, core hardware business under pressure from CGM shift
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040036 |
| Document: mmed-20260603.htm | 0001628280-26-040036 |
| Document: 0001628280-26-040036-index-headers.html | 0001628280-26-040036 |
| Document: 0001628280-26-040036-index.html | 0001628280-26-040036 |
| Document: 0001628280-26-040036.txt | 0001628280-26-040036 |
| 8-K Data (Synthetic) | 0001628280-26-040036 |
Track record
25 reports on MMED
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today 8-K Mixed 6/10 Entry $18.77 Now $18.65 −0.64% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $18.81 Now $18.65 −0.86% settles Dec 15
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $16.71 Now $18.65 +11.61% settles Dec 7
- Oct 22, 202625d ago SC 13G Neutral 4/10 Entry $18.34 Now $18.65 +1.69% settles Nov 20
- Oct 16, 20264w ago SC 13G/A Neutral 4/10 Entry $17.79 to $18.65 Now $18.65 +4.83% ▲ +4.83% +8.30% vs SPY
- Oct 16, 20264w ago 8-K Neutral 6/10 Entry $17.49 to $17.99 Now $18.65 +6.63% ▲ +2.86% +4.02% vs SPY
- Oct 6, 20265w ago EFFECT Neutral 3/10 Entry $19.64 to $18.85 Now $18.65 −5.04% ▼ −4.02% −0.85% vs SPY
- Oct 1, 20266w ago 3 Neutral 2/10 Entry $19.70 to $18.28 Now $18.65 −5.33% ▼ −7.21% −5.40% vs SPY
- Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
- Sep 14, 20269w ago 425 Neutral 4/10 Entry $21.97 to $18.80 Now $18.65 −15.11% ▼ −14.43% −16.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers